HK1220191A1 - 抗焦虑化合物的盐、共晶体和多晶型物 - Google Patents

抗焦虑化合物的盐、共晶体和多晶型物 Download PDF

Info

Publication number
HK1220191A1
HK1220191A1 HK16108260.8A HK16108260A HK1220191A1 HK 1220191 A1 HK1220191 A1 HK 1220191A1 HK 16108260 A HK16108260 A HK 16108260A HK 1220191 A1 HK1220191 A1 HK 1220191A1
Authority
HK
Hong Kong
Prior art keywords
crystals
salts
polymorphs
compound
pharmaceutical compositions
Prior art date
Application number
HK16108260.8A
Other languages
English (en)
Chinese (zh)
Inventor
Luke Flynn Bernard
Paul Dharam
John Harvey Andrew
V Sethuraman Vasu
E Forslund Raymond
Xue Song
LIVINGSTON Rob
Hashash Ahmad
Original Assignee
Bionomics Limited
Ironwood Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionomics Limited, Ironwood Pharmaceuticals, Inc. filed Critical Bionomics Limited
Publication of HK1220191A1 publication Critical patent/HK1220191A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK16108260.8A 2013-03-15 2014-03-14 抗焦虑化合物的盐、共晶体和多晶型物 HK1220191A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361798926P 2013-03-15 2013-03-15
US201361798926P 2013-03-15
PCT/AU2014/000272 WO2014138812A1 (en) 2013-03-15 2014-03-14 Salts, co-crystals, and polymorphs of an anxiolytic compound

Publications (1)

Publication Number Publication Date
HK1220191A1 true HK1220191A1 (zh) 2017-04-28

Family

ID=51535621

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16108260.8A HK1220191A1 (zh) 2013-03-15 2014-03-14 抗焦虑化合物的盐、共晶体和多晶型物

Country Status (9)

Country Link
US (2) US9745296B2 (enExample)
EP (1) EP2970247A4 (enExample)
JP (1) JP2016510768A (enExample)
CN (1) CN105492440A (enExample)
AU (2) AU2014231722B2 (enExample)
CA (1) CA2905570A1 (enExample)
HK (1) HK1220191A1 (enExample)
MX (1) MX2015013059A (enExample)
WO (1) WO2014138812A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6688434B2 (en) 2002-02-22 2004-02-10 Ecolab Inc. Conveyor and lubricating apparatus, lubricant dispensing device, and method for applying lubricant to conveyor
CN105541701A (zh) * 2015-12-11 2016-05-04 吉林大学珠海学院 以顺丁烯二酸为前驱体的去铁酮药物共晶及其制备方法
TWI823344B (zh) * 2015-12-15 2023-11-21 以色列商諾威股份有限公司 用於測量圖案化結構之特性的系統
WO2019109150A1 (en) * 2017-12-07 2019-06-13 Bionomics Limited Methods of treating agitation
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
JP7634525B2 (ja) 2019-09-23 2025-02-21 バイオノミクス リミテッド 治療用製剤およびその使用
AU2023201463A1 (en) * 2023-03-08 2024-09-26 Bionomics Limited Method of treating social anxiety disorder
JPWO2025033432A1 (enExample) * 2023-08-08 2025-02-13

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1656102A2 (en) * 2003-08-21 2006-05-17 Transoral Pharmaceuticals, Inc. Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof
SI2074123T1 (sl) * 2006-10-16 2013-03-29 Bionomics Limited Nove anksiolitične spojine
DE102006060598A1 (de) * 2006-12-21 2008-06-26 Merck Patent Gmbh Tetrahydrobenzoisoxazole
GB0706044D0 (en) * 2007-03-28 2007-05-09 Syngenta Ltd C0-Crystals
US8883802B2 (en) * 2009-12-03 2014-11-11 Astrazeneca Ab Co-crystals of a triazolo [4,5-D] pyrimide platelet aggregation inhibitor
EP2680842A4 (en) * 2011-03-02 2014-10-29 Bionomics Ltd METHOD FOR THE TREATMENT OF A DISEASE OR A SENSE OF THE CENTRAL NERVOUS SYSTEM
CN103649086A (zh) * 2011-05-12 2014-03-19 生态学有限公司 制备萘啶的方法
AU2013204159B2 (en) * 2013-03-15 2015-05-07 Bionomics Limited A Crystalline Form of an Anxiolytic Compound

Also Published As

Publication number Publication date
WO2014138812A1 (en) 2014-09-18
MX2015013059A (es) 2016-08-05
AU2014231722A1 (en) 2015-09-24
US20170362230A1 (en) 2017-12-21
AU2014231722B2 (en) 2016-12-22
EP2970247A1 (en) 2016-01-20
CN105492440A (zh) 2016-04-13
CA2905570A1 (en) 2014-09-18
US10266529B2 (en) 2019-04-23
AU2017201916A1 (en) 2017-04-13
JP2016510768A (ja) 2016-04-11
US9745296B2 (en) 2017-08-29
EP2970247A4 (en) 2016-08-10
US20160185770A1 (en) 2016-06-30
AU2017201916B2 (en) 2018-09-27

Similar Documents

Publication Publication Date Title
MX2015013059A (es) Sales, co-cristales, y polimorfos de un compuesto ansiolitico.
HK1246286A1 (zh) Lrrk2抑制剂及其制备和使用方法
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
CL2015002529A1 (es) Compuestos de tetrahidropirrolotiazina
WO2015200680A8 (en) Prmt5 inhibitors and uses thereof
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
HRP20180678T1 (hr) Spojevi [1,2,4]triazol[1,5-c]kinazolin-5-amina supstituirani s heterobiciklom pogodni za liječenje ili prevenciju poremećaja središnjeg živčanog sustava
WO2014106238A8 (en) Heterocyclic compounds and methods of use thereof
EA201791305A1 (ru) Конденсированные пиримидины для лечения вич
WO2014144545A3 (en) Substituted benzoxazoles and methods of use thereof
WO2015132799A3 (en) Heterocyclic compounds
WO2014031438A3 (en) SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
HK1220355A1 (zh) Mk2抑制劑和其用途
EA201400624A1 (ru) Замещенные 4-фенилпиридины для лечения болезней, связанных с рецептором nk-1
WO2013134353A8 (en) Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
WO2016044641A3 (en) Carm1 inhibitors and uses thereof
TN2015000018A1 (en) 5-ht3 receptor antagonists
TN2017000075A1 (en) Compounds and compositions as raf kinase inhibitors
EP3438048A4 (en) METHOD FOR PRODUCING BINAR-FREE, COAL-BASED, BRIKETTED ACTIVE CARBON
NZ732208A (en) 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139
HK1252631A1 (zh) 替诺福韦艾拉酚胺的共晶体，盐和固体形式
MX370253B (es) Composiciones de compuestos de jasmonato y métodos de uso de las mismas.
AU2015316010A8 (en) Crystalline forms of 6-( (6, 7-dimethoxyquinazolin-4-yl) oxy) -N,2-dimethylbenzofuran-3-carboxamide
WO2014159794A3 (en) Bicyclo [2.2.1] acid gpr120 modulators